Aurobindo Pharma Limited, on June 19, 2026, informed the National Stock Exchange of India (scrip code AUROPHARMA) and BSE Limited (scrip code 524804) that the US Federal Trade Commission has granted approval for the acquisition of the Lannett business. The disclosure was submitted under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and signed by B. Adi Reddy, Company Secretary.
Aurobindo Pharma USA Inc, a wholly owned subsidiary of Aurobindo Pharma Limited, entered into a definitive agreement with LANNETT SELLER HOLDCO, INC to acquire 100% of the membership interest in Lannett Company LLC. The agreement was initially disclosed to the stock exchanges on July 30, 2025. Aurobindo Pharma Limited had informed the NSE and BSE through its letter of the same date about this definitive agreement for the acquisition of Lannett Company LLC.
The FTC approval clears the key regulatory hurdle for the acquisition of Lannett Company LLC by Aurobindo Pharma USA Inc. Under the definitive agreement, Aurobindo Pharma USA Inc will acquire all membership interests in Lannett Company LLC from LANNETT SELLER HOLDCO, INC.
Following the FTC approval, Aurobindo Pharma Limited anticipates the transaction will close before the end of June 2026. Aurobindo Pharma Limited stated it will keep the exchanges informed of any future developments in this matter.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.